MAYNE PHARMA GROUP LIMITED — Director's Dealing 2017

Dec 21, 2017

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Mayne Pharma Group Limited
ABN	76 115 832 963

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Scott Anthony Richards
Date of last notice	7 Dec 2017

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstancesgiving rise to the relevant interest.	HSBC Nominees (Australia) Limited as nominee for Scott AnthonyRichards (1)HSBC Nominees (Australia) Limited as nominee for Scott AnthonyRichards & Susan Marie Richards (2)
Date of change	20 Dec 2017
No. of securities held prior tochange	15,227,881 Ordinary Shares pursuant to executive share loan scheme7,862,906 Ordinary Shares (1) 1,722,463 Ordinary Shares (2)
Class	Ordinary shares
Number acquired	nil
Number disposed	4,000,000
Value/ConsiderationNote: If consideration is non-cash, providedetails and estimated valuation	$2,725,600
No. of securities held after change	15,227,881 Ordinary Shares pursuant to executive share loan scheme3,862,906 Ordinary Shares (1) 1,722,463 OrdinaryShares(2)

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1 ME_131678062_1 (W2003)

Appendix 3Y Change of Director’s Interest Notice

Nature of change

Nature of change On market trade. This completes the share sale that was previously Example: on-market trade, off-market trade, indicated to the market in the Chairman’s AGM speech. exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [434 x 284] intentionally omitted <==

----- Start of picture text ----- Detail of contractNature of interestName of registered holder(if issued securities)Date of changeNo. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changedInterest acquiredInterest disposedValue/ConsiderationNote: If consideration is non-cash, provide detailsand an estimated valuationInterest after change----- End of picture text -----

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailedabove traded during a+closed period where prior writtenclearance was required?	No
If so, was prior written clearance provided to allow the tradeto proceed during this period?	N/a
If prior written clearance was provided, on what date was thisprovided?	N/a

• See chapter 19 for defined terms.

Appendix 3Y Page 2 ME_131678062_1 (W2003)

01/01/2011